Supplementary Figures 1-2 from Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

Authors :: Mark R. Lackner
Andrea Pirzkall
Lukas C. Amler
Garret M. Hampton
Rodney J. Hicks
Brett G.M. Hughes
Bernard M. Fine
Rajiv Raja
Weiqun Liu
Siminder Atwal
Elizabeth A. Punnoose
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: PDF file - 337K

Tools